Type 1 and Type 2 diabetes both involve dysfunction of insulin-producing beta cells — Type 1 through autoimmune destruction, Type 2 through insulin resistance and beta-cell exhaustion.
Type 1 and Type 2 diabetes both involve dysfunction of insulin-producing beta cells — Type 1 through autoimmune destruction, Type 2 through insulin resistance and beta-cell exhaustion. Stem-cell research targets both: placental mesenchymal stem cells and fetal-derived stem cells are studied for their potential to differentiate toward insulin-producing cells, support pancreatic tissue, and dampen autoimmunity. In Type 1 the immune-modulating properties may restrain beta-cell attack; in Type 2 the aim is to ease insulin resistance and support residual reserve. Translating stem-cell-derived beta cells into safe, scalable, durable treatment remains a major unsolved scientific challenge, and all current clinical work is early-stage.
| Индикативна цена · България (ЕС) | €3,000–€8,000 |
|---|---|
| Глобален диапазон на пазарната цена | €6,440–€59,800 (swissmedexpert.com) |
| Основни видове клетки, които се изучават | MSCs from Amniotic Membrane, Fetal Stem Cells |
| Статус на одобрение | Експериментален |
| Регистрирани проучвания (ClinicalTrials.gov) | 236 · 26 recruiting now |
For the clinic's own description, see how Stem Plus describes its Diabetes (Type 1 & 2) programme ↗.
Two hundred thirty-six registered trials and 26 recruiting studies address stem-cell therapy in diabetes — the largest trial landscape among the conditions here. Small cohorts report modest improvements in insulin secretion and HbA1c, but quality is heterogeneous and controls are often absent. Some report temporary reductions in insulin requirement; durability beyond 12 months is poorly documented. No trial has produced insulin independence in Type 1, and sustained insulin-free control in Type 2 is rare.
Depending on assessment, a Diabetes (Type 1 & 2) protocol may draw on:
Indicative European costs are roughly €4,000–€8,000 per course, reflecting cell expansion, purity testing, and frequently multiple infusions. Type 1 protocols may add immune-monitoring; Type 2 protocols often bundle metabolic assessment and follow-up. For context, insulin and monitoring supplies cost roughly €100–€300 monthly and are proven — the stem-cell figure is indicative and unproven.
Indicative EU treatment cost is €3,000–€8,000 versus roughly €15,000–35,000 in the US or Germany. Build your real all-in total with the cost calculator, see the Diabetes (Type 1 & 2) cost-by-country breakdown, or compare the best countries for Diabetes (Type 1 & 2) →
Before booking, check safety & regulation, the recovery climate, дали бихте могли да бъдете кандидат, and which cell type fits Diabetes (Type 1 & 2).
Пълен Захарен диабет (Тип 1 & 2) ЧЗВ → · Разбор на разходите Захарен диабет (Тип 1 & 2) →
We link primary regulators, registries and peer-reviewed research so you can verify everything yourself — plus the treating clinic's own materials.
Useful tools & guides: Съм ли кандидат? · Какъв тип клетки? · Types of clinics & best countries · Калкулатор на разходи
Медицински преглед от редакционния екип на StemCellAtlas с Dr Polina Krasenova (Haematologist · Clinical Haematology & Integrative Oncology · 15+ yrs cell therapy) на партньорската клиника Stem Plus (София), спрямо ISSCR, FDA и EMA указания. Educational information, not medical advice; figures indicative.
GMP-сертифицирана регенеративна медицина в сърцето на ЕС — от 3 000–8 000 €, част от цените в САЩ или Германия. Персонализирани протоколи за пациенти от над 50 държави.
Безплатна медицинска оценка